Ischemic Heart Disease (IHD) Drugs Global Market Report 2024

The ischemic heart disease (ihd) drugs market size has grown strongly in recent years. It will grow from $6.02 billion in 2023 to $6.36 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth observed in the historical period can be attributed to several factors, including the rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives promoting cardiovascular health, collaborations for clinical trials, and favorable insurance coverage and reimbursement policies.

The ischemic heart disease (ihd) drugs market size is expected to see steady growth in the next few years. It will grow to $7.57 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The anticipated growth in the forecast period can be attributed to trends such as aging population patterns, the adoption of personalized medicine approaches, an increased emphasis on cardiovascular prevention, global health policies, and international research collaborations. Major trends expected in the forecast period include a shift towards precision medicine approaches, a focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, the integration of anti-inflammatory agents, and the development of antithrombotic and antiplatelet drugs.

The growth in the prevalence of obesity and diabetes is expected to drive the expansion of the ischemic heart disease (IHD) drugs market. Diabetes, a chronic metabolic disease characterized by elevated blood glucose levels, and obesity, a condition marked by excess body fat accumulation, pose significant health risks. Ischemic heart disease drugs are commonly prescribed for individuals with obesity and diabetes to manage cardiovascular risk factors such as hypertension and dyslipidemia, thereby mitigating the risk of ischemic heart disease. For example, the World Obesity Federation reported in March 2023 that obesity rates are expected to double among boys and more than double among girls by 2035. The projected increase in the number of people with obesity is estimated to reach 2.7 billion by 2025. Additionally, the International Diabetes Federation noted in December 2021 that diabetes affected 537 million adults in 2021, with predictions of reaching 643 million by 2030 and 783 million by 2045. Consequently, the growing prevalence of obesity and diabetes serves as a key driver for the growth of the ischemic heart disease (IHD) drugs market.

The increasing incidence of heart failure is another factor expected to contribute to the growth of the ischemic heart disease (IHD) drug market. Heart failure, a chronic condition where the heart muscle cannot pump enough blood, often leads to symptoms such as fatigue and shortness of breath. Ischemic heart disease drugs play a crucial role in treating heart failure by reducing risk factors and symptoms associated with IHD. These medications can be particularly beneficial for heart failure patients with reduced ejection fractions and high resting heart rates. For instance, data from the Heart Failure Society of America in September 2023 indicates that 6.7 million Americans over 20 years of age have heart failure, and this prevalence is expected to increase to 8.5 million Americans by 2030. The rising incidence of heart failure is a key driver for the growth of the ischemic heart disease (IHD) drug market.

The high cost of treatment is poised to be a potential restraint for the ischemic heart disease (IHD) drugs market in the future, as it may impede access to care for patients facing financial constraints. The elevated cost of IHD treatment can result in delayed diagnosis and treatment, heightening the risk of complications and adversely affecting the sales of IHD drugs. Affordability challenges may make it difficult for patients to access the necessary care, leading to potential financial hardships. For instance, data published by GoodRx Health in August 2022 highlighted heart disease as one of the most expensive health conditions to treat in the US. Even with insurance, out-of-pocket expenses for a heart condition often exceed $2,000 per year. Atherosclerosis, contributing to thickening or hardening of the arteries, can lead adults under 65 to incur annual out-of-pocket medical expenses exceeding $2,000, in addition to insurance premiums. Patients with heart failure may face annual out-of-pocket expenses reaching $5,000. Consequently, the high cost of treatment stands as a significant barrier to growth in the ischemic heart disease (IHD) drugs market.

Major companies operating in the ischemic heart disease (IHD) drugs market are intensifying their focus on developing innovative platelet inhibitors, including intravenous P2Y12 platelet inhibitors, to gain a competitive advantage. Intravenous P2Y12 platelet inhibitors are medications administered directly into the bloodstream to prevent platelet activation and aggregation, reducing the risk of periprocedural myocardial infarction (MI), a type of ischemic heart disease. For example, MSN Laboratories Private Limited, an India-based research-based pharmaceutical company, launched CANREAL injection (Cangrelor) in October 2021. This intravenous P2Y12 platelet inhibitor is recognized for its rapid onset and offset of platelet inhibition, addressing both delayed and prolonged antiplatelet activity. It serves as a bioequivalent generic drug indicated as an adjunct to percutaneous coronary intervention to reduce the risk of myocardial infarction (MI).

In August 2021, Philip Morris International Inc., a US-based tobacco company, acquired OtiTopic Inc. for an undisclosed amount. This acquisition reflects Philip Morris International's strategic move to expand its portfolio of 'beyond nicotine' products and enhance its pipeline of inhaled therapeutic products. OtiTopic Inc., a US-based manufacturer, focuses on respiratory drugs for myocardial infarction (MI), a specific type of ischemic heart disease.

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC.

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ischemic heart disease (IHD) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ischemic heart disease (IHD) drugs refer to medications employed in the management and treatment of a condition characterized by reduced blood flow to the heart muscle, often due to narrowing of the coronary arteries. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

The primary drug classes encompassed by ischemic heart disease (IHD) drugs include anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs are pharmacological agents targeting and reducing abnormal lipid levels (such as cholesterol and triglycerides) in the bloodstream to mitigate the risk of cardiovascular disease. These drugs are utilized in the treatment of various conditions, including angina pectoris and myocardial infarction, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The ischemic heart disease (IHD) drugs market research report is one of a series of new reports that provides ischemic heart disease (IHD) drugs market statistics, including ischemic heart disease (IHD) drugs industry global market size, regional shares, competitors with a ischemic heart disease (IHD) drugs market share, detailed ischemic heart disease (IHD) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ischemic heart disease (IHD) drugs industry. This ischemic heart disease (IHD) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ischemic heart disease (IHD) drugs market consists of sales of antiarrhythmic drugs, anticoagulants, anti-anginal medications, nitroglycerin and nitrates, statins, and antiplatelet agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.